Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The Value of Progression-Free Survival in the Perspective of Patients with Multiple Myeloma and Treating Physicians: Research Findings from the US, EU4, UK, Brazil, and Japan.

Clinical lymphoma, myeloma & leukemia·2026

Same author

Targeted Radiation, Unintended Evolution.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same author

[Update of S3 guideline on metastatic prostate cancer-guideline recommendations and expert consensus].

Urologie (Heidelberg, Germany)·2026

Same author

Time dependent outcomes modeling in a real-world analysis of the molecular tumor board at University Cancer Center Hamburg (2016-2022).

The oncologist·2026

Same author

Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer.

The New England journal of medicine·2026

Same author

Overexpression of the ERG oncogene in prostate cancer identifies candidates for PARP inhibitor-based radiosensitization.

The Journal of clinical investigation·2026

Same journal

Toward Interpretable Machine Learning Models for Grading Prostate Cancer: A Multicenter Development and Validation Study.

Clinical genitourinary cancer·2026

Same journal

Primary Mediastinal Seminoma: Clinical Characteristics and Outcomes.

Clinical genitourinary cancer·2026

Same journal

Time to Treatment Initiation and Survival in Patients With Muscle-Invasive Bladder Cancer (MIBC).

Clinical genitourinary cancer·2026

Same journal

PROTEUS and the Perioperative Intensification Era in High-risk Prostate Cancer.

Clinical genitourinary cancer·2026

Same journal

Circulating Tumor DNA After Radical Cystectomy as a Marker of Minimal Residual Disease in Muscle-Invasive Bladder Cancer: A Literature Review.

Clinical genitourinary cancer·2026

Same journal

Trophoblastic-Differentiated Urothelial Carcinoma: Real-World Sequencing and Clinical Implications.

Clinical genitourinary cancer·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 7, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Treatment Patterns Among Androgen Receptor Pathway Inhibitor-Experienced Patients With Metastatic

Gunhild von Amsberg¹, Alison Bulkley², Marc DeCongelio²

¹University Cancer Center Hamburg and Martini-Klinik, Hamburg, Germany.

Clinical Genitourinary Cancer

|March 10, 2026

Summary

This summary is machine-generated.

Sequential androgen receptor pathway inhibitor (ARPI) use is common in metastatic castration-resistant prostate cancer (mCRPC) after initial ARPI treatment. Treatment choices, including sequential ARPIs or chemotherapy, depend on patient performance status.

Keywords:

Abiraterone Docetaxel Enzalutamide Real-world evidence Treatment sequencing

More Related Videos

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

Related Experiment Videos

Last Updated: Jun 7, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

Area of Science:

Oncology
Pharmacology
Clinical Medicine

Background:

Androgen receptor pathway inhibitors (ARPIs) are increasingly used in earlier prostate cancer treatment stages.
Real-world data on treatment patterns following ARPI use in pre-metastatic castration-resistant prostate cancer (mCRPC) are limited.
This study examines contemporary treatment strategies for mCRPC patients with prior ARPI exposure.

Purpose of the Study:

To describe real-world treatment patterns in ARPI-experienced mCRPC patients.
To analyze treatment sequences following initial ARPI therapy.
To identify factors influencing treatment selection in this population.

Main Methods:

Retrospective, noninterventional study of 1014 mCRPC patients from August-October 2023.
Physicians completed electronic case reports based on medical records of patients with prior ARPI and mCRPC therapy.
The first treatment for mCRPC in ARPI-experienced patients was defined as the index line.

Main Results:

82.6% of patients received initial ARPI in pre-mCRPC settings; 17.4% received it as first-line mCRPC treatment.
The index line treatment included another ARPI (48.4%) or docetaxel (35%).
Common sequences were abiraterone→docetaxel (16.1%) and abiraterone→enzalutamide (10.9%). Taxane therapy was more common in patients with ECOG 0-1 (42%-46%) vs. ECOG ≥ 2 (29%).

Conclusions:

Sequential ARPI use is a common international practice, potentially to mitigate chemotherapy toxicity.
Treatment choice between sequential ARPI and chemotherapy varies with patient performance status.
There is a need for novel therapies for ARPI-refractory prostate cancer.